Clinical trials: Neuralgia
Peripheral Post-surgical Neuropathic Pain
AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain
This is a Phase IIa randomized, double-blind, placebo-controlled study. The study objective is to investigate the efficacy and safety of repeat oral dosing of the investigational medicinal product (IMP) AP-325 for the treatment…
- Trial name
- NCT04429919
- Testing
- AP-325
- Where
- 32 sites in Belgium, Czechia and 3 more
- Volunteers
- 99 people
- Sponsor
- Algiax Pharmaceuticals GmbH
Neuropathic Pain
Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain
The trial is designed to evaluate the efficacy and tolerability of carbamazepine in neuropathic pain in diabetic patients
- Trial name
- NCT01089855
- Testing
- Carbamazepine
- Where
- Morocco
- Volunteers
- 123 people
- Sponsor
- Novartis
Painful Lumbar Radiculopathy, Sciatica
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
The primary objective of the study is to assess the efficacy of Intravenous (IV) BG00010 (Neublastin) in improving pain in painful lumbar radiculopathy participants when administered 3 times per week for 1 week.
- Conditions
- Painful Lumbar Radiculopathy, Sciatica, Radiculopathy
- Trial name
- SPRINT (NCT01873404)
- Testing
- BG00010
- Where
- 25 sites in United States
- Volunteers
- 183 people
- Sponsor
- Biogen
Neuropathic Pain in Cancer
Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer
The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the neuropathic pain associated with cancer, in addition to explore the effective concentration of NPC-06.
- Trial name
- NCT03773055
- Testing
- NPC-06
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Nobelpharma
Postherpetic Neuralgia
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
- Trial name
- RELIEF-PHN1 (NCT04662281)
- Testing
- LX9211
- Where
- 32 sites in United States, Czechia and 1 more
- Volunteers
- 79 people
- Sponsor
- Lexicon Pharmaceuticals